Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors

Trial Profile

Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 02 May 2017

At a glance

  • Drugs Gallium 68-DOTATOC (Primary)
  • Indications Brain cancer
  • Focus Diagnostic use
  • Most Recent Events

    • 27 Apr 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Mar 2017.
    • 27 Apr 2017 Status changed from suspended to withdrawn prior to enrolment.
    • 07 Sep 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top